Antibody response to heat-inactivated hepatitis B vaccine (CLB-3 micrograms) in hemodialysis patients and occupational risk personnel: a one year follow-up
Yoshida, F.T.; Takahashi, C.; Mercadante, L.A.; Camargo, I.F.; Schatzmayr, H.G.
Revista do Instituto de Medicina Tropical de Sao Paulo 30(1): 11-16
1988
ISSN/ISBN: 0036-4665 PMID: 2975824 Document Number: 307534
Immune response against hepatitis B vaccine (CLB-3.mu.g) was evaluated in 59 hemodialysis patients and 20 occupational risk personnel. Seroconversion was induced in 52.2% and 70.0% respectively. Twelve months after the first dose, 37.5% of patients and 60.0% of occupational risk personnel had detectable anti-HBs level. Antibody level was expressed in sample ratio units (SRU). Considering only the responders, in the patients group 38.7% had a low anti-HBs response (2.1-9.9 SRU) 32.3% a medium response (10-99.9 SRU) and 29.0% a high response (>100 SRU) while in occupational risk personnel these values were 14.3%, 64.3% and 21.4% respectively. The authors suggest the use of HBV vaccines with more elevated HBsAg concentration or a reinforced immunization schedule to improve the anti-HBs response not only for patients but also for healthy persons.